Properties
What is it?
International Nonproprietary Name - ketorolac tromethamine Clinical-pharmacological group: Anti-inflammatory agents → Non-steroidal anti-inflammatory agents → Non-steroidal anti-inflammatory agents for systemic use → Propionic acid derivatives with pronounced analgesic effect Dosage form: Solution for injection. Description: Clear, colorless or slightly yellow solution. Composition 1 ampoule of the preparation contains: Active substance: ketorolac tromethamine 30 mg. Excipients: disodium edetate, ethyl alcohol, sodium chloride, sodium hydroxide, water for injection. Pharmacotherapeutic group Non-steroidal anti-inflammatory and antirheumatic drugs. Indications - Moderate and severe pain syndrome of various origins (including postoperative pain, pain during oncological diseases). Method of administration and dosage Solution for intramuscular and intravenous administration. Intravenous administration of ketorolac tromethamine should last at least 15 seconds. Intramuscular administration of Medrolgin should be slow and deep into the muscle. Local side effects can be avoided by applying pressure to the injection site for 15-30 seconds after administration. Epidural and intrathecal administration of the preparation is contraindicated. For relief of moderate to severe acute pain in adult patients under 65 years of age weighing more than 50 kg, no more than 60 mg is administered intramuscularly at a time (including oral dose of ketorolac); usually 30 mg every 6 hours; intravenously - 30 mg (no more than 15 doses in 5 days). The maximum daily dose should not exceed 120 mg. In patients weighing <50 kg or with chronic renal failure, as well as over 65 years of age, no more than 30 mg is administered intramuscularly at a time (including oral dose of ketorolac); usually 15 mg (no more than 20 doses in 5 days); intravenously - no more than 15 mg every 6 hours (no more than 20 doses in 5 days). The maximum daily dose should not exceed 60 mg. Duration of treatment is no more than 5 days. Contraindications - Hypersensitivity to ketorolac or any component of the preparation; - Erosive-ulcerative lesions of the gastrointestinal tract in the exacerbation phase, peptic ulcer, history of gastrointestinal bleeding; - Bronchial asthma, rhinitis, angioedema or urticaria caused by acetylsalicylic acid or other non-steroidal anti-inflammatory drugs; - Prophylactic analgesia before surgery and intraoperative use (due to the possibility of suppressing platelet aggregation and risk of bleeding); - Moderate and severe forms of renal failure, risk of renal failure in hypovolemia or dehydration; - Complete or partial syndrome of nasal polyps, Quincke's edema or bronchospasm; - Suspected or confirmed cerebrovascular hemorrhage, surgical interventions with a high risk of incomplete cessation of bruising or bleeding; - Blood clotting disorders, conditions with a high risk of bleeding or incomplete hemostasis; - Concomitant treatment with other non-steroidal anti-inflammatory drugs or pentoxifylline; - Pregnancy, labor and lactation period; - Age under 16 years.